uniQure (NASDAQ:QURE) Receives $55.43 Consensus Price Target from Brokerages

uniQure (NASDAQ:QUREGet Rating) has earned a consensus rating of “Buy” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $55.43.

A number of analysts recently weighed in on QURE shares. StockNews.com started coverage on shares of uniQure in a report on Thursday, March 31st. They set a “hold” rating for the company. Chardan Capital reduced their target price on shares of uniQure from $95.00 to $65.00 in a report on Wednesday, March 30th. Zacks Investment Research downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Thursday, March 3rd. Truist Financial reduced their price target on shares of uniQure from $90.00 to $51.00 in a research report on Wednesday, April 13th. Finally, UBS Group upgraded shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Thursday, March 17th.

uniQure stock opened at $18.75 on Friday. The company has a 50 day moving average of $17.24. The company has a quick ratio of 17.09, a current ratio of 17.09 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $871.07 million, a PE ratio of 2.69 and a beta of 1.05. uniQure has a 12-month low of $14.29 and a 12-month high of $38.80.

uniQure (NASDAQ:QUREGet Rating) last issued its earnings results on Friday, February 25th. The biotechnology company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.89. The firm had revenue of $57.69 million during the quarter, compared to analysts’ expectations of $25.12 million. uniQure had a net margin of 62.90% and a return on equity of 64.35%. As a group, equities research analysts forecast that uniQure will post -2.67 earnings per share for the current year.

In related news, CEO Matthew C. Kapusta sold 10,195 shares of the firm’s stock in a transaction on Monday, February 28th. The shares were sold at an average price of $16.70, for a total value of $170,256.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Alexander Edward Kuta III sold 3,405 shares of the firm’s stock in a transaction on Monday, February 28th. The shares were sold at an average price of $16.72, for a total transaction of $56,931.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,111 shares of company stock valued at $698,006. Insiders own 2.66% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in uniQure by 1.2% in the 4th quarter. BlackRock Inc. now owns 4,293,805 shares of the biotechnology company’s stock worth $89,053,000 after purchasing an additional 50,307 shares during the last quarter. Invesco Ltd. grew its position in uniQure by 3.4% in the 4th quarter. Invesco Ltd. now owns 2,374,235 shares of the biotechnology company’s stock worth $49,241,000 after purchasing an additional 77,856 shares during the last quarter. State Street Corp lifted its holdings in shares of uniQure by 24.4% during the 4th quarter. State Street Corp now owns 2,157,684 shares of the biotechnology company’s stock worth $44,750,000 after acquiring an additional 423,019 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of uniQure by 129.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,965,520 shares of the biotechnology company’s stock worth $40,765,000 after acquiring an additional 1,109,520 shares during the period. Finally, 683 Capital Management LLC lifted its holdings in shares of uniQure by 76.2% during the 4th quarter. 683 Capital Management LLC now owns 1,253,200 shares of the biotechnology company’s stock worth $25,992,000 after acquiring an additional 541,845 shares during the period. Institutional investors and hedge funds own 81.40% of the company’s stock.

uniQure Company Profile (Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

See Also

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.